Geode Capital Management LLC grew its holdings in Bruker Co. (NASDAQ:BRKR – Get Rating) by 1.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,691,045 shares of the medical research company’s stock after acquiring an additional 18,665 shares during the quarter. Geode Capital Management LLC owned 1.15% of Bruker worth $115,582,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Bruker by 12.7% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 44,993 shares of the medical research company’s stock worth $3,075,000 after acquiring an additional 5,054 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Bruker by 11.2% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,167,283 shares of the medical research company’s stock worth $148,134,000 after acquiring an additional 218,864 shares in the last quarter. Capital Fund Management S.A. increased its holdings in shares of Bruker by 51.1% in the fourth quarter. Capital Fund Management S.A. now owns 183,257 shares of the medical research company’s stock worth $12,526,000 after acquiring an additional 61,994 shares in the last quarter. Fayez Sarofim & Co bought a new position in shares of Bruker during the fourth quarter worth about $225,000. Finally, Quadrant Capital Group LLC grew its holdings in shares of Bruker by 175.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,051 shares of the medical research company’s stock worth $72,000 after buying an additional 669 shares in the last quarter. 70.40% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. Citigroup increased their price objective on Bruker from $90.00 to $95.00 in a report on Friday, May 5th. StockNews.com assumed coverage on Bruker in a report on Thursday, May 18th. They set a “strong-buy” rating for the company. The Goldman Sachs Group increased their price objective on Bruker from $63.00 to $70.00 and gave the stock a “sell” rating in a report on Wednesday, April 19th. Finally, UBS Group increased their price objective on Bruker from $92.00 to $98.00 in a report on Friday, May 5th. One investment analyst has rated the stock with a sell rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $84.50.
Bruker Stock Performance
Bruker (NASDAQ:BRKR – Get Rating) last issued its quarterly earnings results on Thursday, May 4th. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.55 by $0.09. Bruker had a return on equity of 34.71% and a net margin of 11.89%. The firm had revenue of $685.30 million during the quarter, compared to analysts’ expectations of $639.63 million. During the same period in the prior year, the firm posted $0.49 earnings per share. The business’s quarterly revenue was up 15.2% compared to the same quarter last year. Analysts predict that Bruker Co. will post 2.58 earnings per share for the current fiscal year.
Bruker Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 16th. Stockholders of record on Thursday, June 1st will be given a $0.05 dividend. The ex-dividend date of this dividend is Wednesday, May 31st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.26%. Bruker’s payout ratio is 9.52%.
Insider Activity
In other news, CEO Frank H. Laukien sold 148,230 shares of the firm’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $81.02, for a total value of $12,009,594.60. Following the completion of the sale, the chief executive officer now directly owns 38,349,926 shares of the company’s stock, valued at $3,107,111,004.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Frank H. Laukien sold 148,230 shares of the firm’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $81.02, for a total value of $12,009,594.60. Following the completion of the sale, the chief executive officer now directly owns 38,349,926 shares of the company’s stock, valued at $3,107,111,004.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Frank H. Laukien sold 16,435 shares of the firm’s stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $79.21, for a total value of $1,301,816.35. Following the completion of the sale, the chief executive officer now directly owns 38,352,034 shares of the company’s stock, valued at $3,037,864,613.14. The disclosure for this sale can be found here. Insiders sold a total of 336,478 shares of company stock valued at $26,690,354 over the last three months. Insiders own 28.20% of the company’s stock.
Bruker Profile
Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI Nano, and Bruker Energy and Supercon Technologies (BEST).
Featured Articles
- Get a free copy of the StockNews.com research report on Bruker (BRKR)
- What is a Growth Stock Mutual Fund?
- 10 Best Airline Stocks to Buy
- Ollie’s Bargain Outlet Goes On Sale
- Campbell Soup Company Leads Staples Stocks Into The Buy Zone
- Netflix Collaboration Fuels IAS, DoubleVerify Stock Surge
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR – Get Rating).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
